Article

Verteporfin for injection

The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
Related Content
OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain
July 18th 2025

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Harrow enters into agreement with Samsung Bioepis for commercial rights to its ophthalmology biosimilar portfolio
July 17th 2025

Harrow enters into agreement with Samsung Bioepis for commercial rights to its ophthalmology biosimilar portfolio

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap
July 17th 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap

FDA grants fast track designation to Sanofi’s SAR446597
July 17th 2025

FDA grants fast track designation to Sanofi’s SAR446597

© 2025 MJH Life Sciences

All rights reserved.